Project Grant R41TR004880
Award Date 12/15/23
Completion Date 12/14/24
Dollars Obligated $325K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Ithaca, NY 14853, USA
Similar Awards
- This National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) Project Grant award of $285,444, effective August 15, 2025 through August 14, 2026 (CFDA 93.350), aims to develop recombinant human enzyme panels representing genetic variants of drug-metabolizing enzymes present in the U.S. patient population. The goal is to bridge shortcomings in current in vitro drug metabolism testing, which typically relies on liver microsomes or hepatocytes from...
- This $305,352 Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) supports the development of a quantitative, home monitoring point-of-care test for determining total blood homocysteine (THCY) levels. The funding will allow Analytical Diagnostic Solutions Inc., a for-profit S corporation based in New Jersey, to create the "HCY NOW" device, which aims to significantly improve the management of homocystinurias (HCUs) - a group of...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $1,050,276 Project Grant to Syntr Health Technologies, Inc. on September 25, 2025 under the CFDA 93.350 Federal Grant Program. This funding supports the development and automation of an FDA-cleared CD-microfluidic platform for rapid tissue microsizing. The platform technology can process a variety of tissue types, including cancer tumors and adipose tissue, to enable single-cell analysis and regenerative medical...
- This Project Grant award from the National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, provides $329,272 to Capienda Biotech, LLC to develop a high-throughput kinetic system for small-molecule drug discovery. The goal is to create an innovative instrument that can rapidly characterize the binding kinetics of compounds targeting human cyclin-dependent kinases, which are important oncology targets. This will help medicinal chemists identify drug candidates...
- This Project Grant awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), seeks to develop and characterize a point-of-care testing platform to enable rapid, bedside, or at-home measurement of tacrolimus (TAC), an immunosuppressive drug critical for organ transplant patients. The $306,299 award, effective July 1, 2025 through June 30, 2026, will fund the adaptation of the D4 immunoassay platform originally developed at...
- The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), through the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded a $175,964 Project Grant to Hepatx Corporation in Palo Alto, CA on May 13, 2025. The grant aims to develop a proteomic assay, or blood test, to monitor the success of cell transplantation therapies, such as hepatocyte (liver cell) transplantation, for treating chronic diseases. This novel assay would enable the...
- The National Center for Advancing Translational Sciences (NCATS) awarded a $1,077,369 Project Grant to Captis Diagnostics Inc. on March 11, 2025 to develop and commercialize a proprietary Lipid Nanoprobe (LNP) system for the rapid, efficient, and cost-effective isolation of extracellular vesicles (EVs) from non-invasive bodily fluids. The project, funded under NCATS' Federal Grant Program (CFDA 93.350), aims to unlock the potential of EVs in multi-omics-based disease molecular characterization...
- The National Center for Advancing Translational Sciences (NCATS), under CFDA Program 93.350, has awarded a $331,034 Project Grant to Vector Surgical LLC to develop the Gene Therapy Catheter (GTC) - an electrical pulsing device designed to enhance the delivery of adeno-associated virus (AAV) gene therapy to the liver. The GTC aims to improve the efficiency and safety of liver-directed gene therapies by combining local delivery with electrical pulsing and a double-balloon system to isolate the...
- The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
- The federal Project Grant award from the National Center for Advancing Translational Sciences (NCATS), part of the 93.350 CFDA program, will support the development of a novel biosensor for the detection of bacterial endotoxins. Through this $290,066 award, the awardee Monod Bio, Inc. will focus on (I) computational design and experimental selection of functional lipopolysaccharide (LPS) bioluminescent biosensors, (II) in vitro evolution of these biosensors to optimize sensitivity and stability,...